AU Patent

AU2026201834A1 — Ophthalmic pharmaceutical compositions and uses thereof

Assigned to Alcon Inc · Expires 2026-04-02 · 0y expired

What this patent protects

Provided herein are ophthalmic pharmaceutical compositions comprising (1R,2S,5R)-2- isopropyl-N-(4-methoxyphenyl)-5-methylcyclohexane-1-carboxamide (WS-12) for effectively treating dry eye in a subject in need thereof, effectively reducing dry eye in a subject in need thereof, ef…

USPTO Abstract

Provided herein are ophthalmic pharmaceutical compositions comprising (1R,2S,5R)-2- isopropyl-N-(4-methoxyphenyl)-5-methylcyclohexane-1-carboxamide (WS-12) for effectively treating dry eye in a subject in need thereof, effectively reducing dry eye in a subject in need thereof, effectively reducing the likelihood of dry eye in a subject in need thereof, or for treating, preventing, or ameliorating signs or symptoms of dry eye in a subject in need thereof.

Drugs covered by this patent

Patent Metadata

Patent number
AU2026201834A1
Jurisdiction
AU
Classification
—
Expires
2026-04-02
Drug substance claim
No
Drug product claim
No
Assignee
Alcon Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.